When Amgen Inc. (NASDAQ: AMGN) released its third-quarter financial results after the markets closed on Tuesday, the firm said that it had $3.66 in earnings per share (EPS) and $5.7 billion in revenue. That compared with consensus estimates of $3.53 in EPS and $5.63 billion in revenue, as well as the $3.69 per share on $5.9 billion posted in the same period from last year.
During the most recent quarter, revenues decreased 3% year over year, reflecting the impact of biosimilar and generic competition against key products. Product sales fell 1% in the period as well.
In terms of its product sales, Amgen reported as follows:
- Prolia sales increased 18% year over year to $630 million
- Evenity sales were $59 million
- Repatha sales increased 40% to $168 million
- Aimovig sales were $66 million
- Parsabiv sales increased 54% $157 million
- Kyprolis sales increased 15% to $266 million
- Xgeva sales increased 10% to $476 million
- Vectibix, sales increased 8% to $196 million
- Nplate sales increased 10% to $195 million
- Blincyto sales increased 47% to $85 million
- Biosimilar sales were $173 million.
- Enbrel sales increased 6% to $1.37 billion
- Neulasta sales decreased 32% to $711 million
- Neupogen sales decreased 36% to $54 million
- Epogen sales decreased 15% to $215 million
- Aranesp sales decreased 5% to $452 million
- Sensipar/Mimpara sales decreased 73% to $109 million
Looking ahead to the full year, the company expects to see EPS in the range of $14.20 to $14.45 and revenue between $22.8 billion and $23.0 billion. Consensus estimates are calling for $14.39 in EPS and $22.85 billion in revenue for the year.
Robert A. Bradway, board chair and chief executive, commented:
Amgen continues to execute well in a dynamic environment, with many of our innovative medicines delivering double-digit, volume-driven growth, complemented by the strong performance of our recently launched biosimilar products. We continue to advance numerous first-in-class medicines in our pipeline, while also pursuing external opportunities that will contribute to our long-term growth, such as our pending acquisition of Otezla.
Shares of Amgen closed Tuesday at $208.99, with a 52-week range of $166.30 to $211.90. The consensus price target is $215.62. Following the announcement, the stock was initially flat in the after-hours trading session.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
